Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of...

Related Keywords

Japan ,United States ,South Korea ,Canada ,American ,Korea ,America ,Canadian ,Roger Dansey ,Exchange Commission ,American Society Of Clinical Oncology ,National Library Of Medicine ,Linkedin ,Youtube ,Leukemia Lymphoma Society ,College Of Medicine ,Pfizer Inc ,Catholic University Of Korea ,Pfizer ,Clinical Oncology ,Annual Meeting ,Jeunga Kim ,Catholic University ,Chief Development Officer ,North America ,Diffuse Largeb Cell Lymphoma ,Prescribing Information ,Pfizer Oncology ,Breakthroughs That Change Patient Lives ,Annual Report ,Looking Information ,Factors That May Affect Future ,Diffuse Largeb Cell ,Updated April ,